# Clinical Implications Summary

## Target Audience
**Primary Care Physicians, Obstetrician-Gynecologists, Nurse Practitioners, Physician Assistants, and other clinicians caring for women of reproductive age.**

---

## Key Clinical Recommendations for Practice

### Screening Recommendations

- **Screen all women aged 18-45 years with unexplained fatigue** using serum ferritin, regardless of hemoglobin status
  - Current anemia-focused screening misses 80-85% of iron-deficient women
  - Fatigue with normal hemoglobin warrants ferritin assessment
  - Priority groups: women with ferritin <30 μg/L have highest symptom burden

- **Routine ferritin screening for high-risk populations**:
  - Women with heavy menstrual bleeding (PBAC ≥100 or self-reported "very heavy" periods)
  - Multiparous women (≥2 live births), especially with short interpregnancy intervals
  - Women aged 35-45 years (peak IDWA prevalence decade)
  - Mexican American women (11.6% IDWA prevalence vs. 6.5-8.8% in other groups)
  - Women with previous iron deficiency anemia history
  - Vegetarians/vegans and women with low iron intake

- **Diagnostic thresholds to use in clinical practice**:
  - **Definite IDWA**: Ferritin <15 μg/L with hemoglobin ≥12.0 g/dL
  - **Probable IDWA**: Ferritin 15-25 μg/L with symptoms suggestive of iron deficiency
  - **Optimal range**: Ferritin >50 μg/L (associated with minimal fatigue in RCTs)
  - Note: 15-25 μg/L range represents "iron-deficient erythropoiesis" per physiologically-based studies

### When to Recommend Supplementation

**Initiate iron supplementation for**:

1. **Documented IDWA** (ferritin <15 μg/L, normal Hb)
   - Start moderate-dose iron (18-27 mg elemental iron daily)
   - Duration: Minimum 3 months; typically 6 months total
   - Follow-up ferritin at 8-12 weeks

2. **Symptomatic women with borderline ferritin** (15-30 μg/L)
   - Consider 8-12 week therapeutic trial if fatigue, cognitive symptoms, or exercise intolerance present
   - Reassess symptoms and ferritin at completion
   - Continue if symptomatic improvement documented

3. **Women with heavy menstrual bleeding** (even with normal ferritin)
   - Prophylactic iron may prevent depletion
   - Start at 18 mg/day; increase if deficiency develops
   - Coordinate with gynecologic management of HMB

4. **Preconception and pregnant women**
   - Preconception: Optimize ferritin >30 μg/L before conception
   - Pregnancy: Universal supplementation per ACOG guidelines (27 mg/day)

**Dosing recommendations based on this study**:

| Dose Range | Elemental Iron | Formulation Examples | Indication |
|------------|----------------|---------------------|------------|
| **Low** | 1-17 mg/day | Standard multivitamins | Maintenance, low-risk women |
| **Moderate** (Optimal) | 18-27 mg/day | Prenatal vitamins, women's multivitamins with iron | **First-line for IDWA** |
| **High** | ≥28 mg/day | Prescription iron (FeSO4 325mg = 65mg elemental) | Severe deficiency, physician-directed |

**Note**: This study found **moderate doses (18-27 mg/day)** showed the strongest association with higher ferritin levels (β=0.207, p<0.001), exceeding effects of both lower and higher doses.

### Patient Counseling Points

**When discussing IDWA with patients, emphasize**:

- **IDWA is a real condition with real symptoms**:
  - Fatigue affects 30-50% of women with IDWA
  - Cognitive impairment (concentration, memory) documented
  - Exercise intolerance common even without anemia
  - Quality of life impact comparable to mild chronic diseases

- **Treatment works**:
  - Randomized trials show 30-48% reduction in fatigue with iron supplementation
  - Ferritin improvements typically seen within 6-8 weeks
  - Full symptom resolution may require 12+ weeks

- **Dosing practicalities**:
  - Daily moderate dose (18-27 mg) preferred over high-dose intermittent
  - Take with vitamin C (orange juice) to enhance absorption
  - Avoid taking with calcium, coffee, tea, or antacids (reduce absorption)
  - Side effects (constipation, nausea, dark stools) more common at high doses

- **Duration matters**:
  - Minimum 3 months to replete stores
  - Total 6 months common for sustained improvement
  - Longer if ongoing iron losses (heavy periods) persist

- **Address underlying causes**:
  - Heavy menstrual bleeding requires gynecologic evaluation
  - Dietary counseling: emphasize heme iron sources (red meat, poultry), vitamin C pairing
  - Evaluate for malabsorption if poor response to oral iron

### Monitoring Strategies

**Laboratory monitoring schedule**:

| Timepoint | Assessment | Action |
|-----------|-----------|--------|
| **Baseline** | Ferritin, hemoglobin, CBC | Establish diagnosis, rule out anemia |
| **8-12 weeks** | Ferritin | Document response; target >30 μg/L |
| **6 months** | Ferritin, hemoglobin | Assess repletion; consider discontinuation |
| **Ongoing** | Ferritin every 3-6 months | If continued supplementation needed |
| **Annually** | Ferritin, symptom review | Long-term monitoring for high-risk women |

**Red flags requiring referral** (Hematology or Gynecology):

- Poor ferritin response after 3 months of compliant therapy (consider IV iron, malabsorption)
- Ferritin >100 μg/L with supplementation (consider hemochromatosis, inflammation)
- Family history of hemochromatosis
- Heavy menstrual bleeding requiring gynecologic intervention
- Pregnancy with documented IDA (may need IV iron)

### Key Takeaways for Clinical Practice

✓ **Screen ferritin, not just hemoglobin** — 80-85% of iron-deficient women have normal hemoglobin  
✓ **Use 15-30 μg/L range as actionable** — Women with ferritin 15-30 μg/L and symptoms warrant treatment  
✓ **Start with moderate doses** — 18-27 mg/day shows optimal association with improved ferritin  
✓ **Monitor response** — Recheck ferritin at 8-12 weeks; expect 30-50% increase  
✓ **Treat for minimum 3-6 months** — Store repletion requires sustained therapy  
✓ **Address HMB concurrently** — Gynecologic management essential for sustained improvement  
✓ **Don't ignore "normal" ferritin 15-30** — This borderline range may cause symptoms  
✓ **Consider prophylaxis for high-risk women** — Heavy periods, multiparity, dietary restrictions  

### ICD-10 Coding

- **E61.1**: Iron deficiency (most appropriate for IDWA)
- **D50.9**: Iron deficiency anemia, unspecified (if anemia present)
- **R53.83**: Other fatigue (if fatigue is presenting complaint)

### Additional Resources for Clinicians

- **WHO Guidelines** (2020): Serum ferritin concentrations for assessment of iron status
- **CDC Iron Recommendations**: https://www.cdc.gov/ncbddd/blooddisorders/index.html
- **ACOG Practice Bulletin**: Anemia in pregnancy (includes IDWA discussion)
- **British Society of Haematology**: Guidelines on iron deficiency anemia management

---

*Clinical Implications Summary for: Iron Deficiency Without Anemia in US Women*  
*Based on NHANES 2015-2020 study (n=6,125) and supporting literature*  
*Date: 2026-01-31*
